Adenosine phosphate

Adenosine (adenosine phosphate) is a small molecule pharmaceutical. Adenosine phosphate was first approved as Adenocard on 1989-10-30. It is known to target transient receptor potential cation channel subfamily M member 4.

Download report

Favorite

Events Timeline

Commercial

Clinical

Drug

Target

Variants

Financial

Trends

Safety

Events Timeline

YTD

Max

Events

FDA approval date

EMA approval date

Patent expiration date

Study first post date

Last update post date

Start date

Primary completion date

Completion date

Results first post date

Mock data
Subscribe for the real data

Commercial

Therapeutic Areas

No data

Trade Name

FDA

EMA

No data

Drug Products

FDA

EMA

New Drug Application (NDA)

Abbreviated New Drug Application (ANDA)

No data

Labels

FDA

EMA

Brand Name	Status	Last Update
9tails premium wrinkle power lifting	unapproved drug other	2019-10-28
a.m	unapproved drug other	2021-04-24
aape continuous renewal	unapproved drug other	2019-08-26
aape continuous renewal eye	unapproved drug other	2019-08-26
aape continuous renewal serum	unapproved drug other	2019-08-26
abalone aqua flood water	unapproved drug other	2017-02-20
abalone crystaldouble ex	unapproved drug other	2017-02-23
abalone crystaldouble ex ampoule	unapproved drug other	2017-03-10
abalone crystaldouble ex bb	unapproved drug other	2017-03-10
abalone crystaldouble ex cc	unapproved drug other	2017-03-10

Show 547 more

Indications

FDA

EMA

No data

Agency Specific

FDA

EMA

No data

Patent Expiration

No data

ATC Codes

No data

HCPCS

Code	Description
J0153	Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds)

Clinical

Clinical Trials

1478 clinical trials

View more details

Mock data
Subscribe for the real data

Indications Phases 4

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Coronary artery disease	D003324	—	I25.1	6	23	32	67	85	205
Leukemia	D007938	—	C95	61	102	17	1	4	150
Myocardial ischemia	D017202	EFO_1001375	I20-I25	3	15	19	39	52	123
Breast neoplasms	D001943	EFO_0003869	C50	37	53	24	1	15	116
Coronary disease	D003327	—	—	2	14	18	35	38	103
Acute coronary syndrome	D054058	EFO_0005672	—	4	8	17	52	24	103
Myocardial infarction	D009203	EFO_0000612	I21	—	7	18	47	31	102
Infarction	D007238	EFO_0009463	—	—	7	15	45	28	94
Syndrome	D013577	—	—	11	17	11	33	17	81
Precursor cell lymphoblastic leukemia-lymphoma	D054198	—	C91.0	23	41	6	2	2	63

Show 110 more

Indications Phases 3

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Myeloid leukemia acute	D015470	—	C92.0	47	94	14	—	2	133
Myelodysplastic syndromes	D009190	—	D46	33	54	5	—	—	74
Myeloid leukemia	D007951	—	C92	27	50	8	—	2	71
Lymphoid leukemia	D007945	—	C91	8	17	6	—	2	28
Non-hodgkin lymphoma	D008228	—	C85.9	11	20	1	—	—	27
Preleukemia	D011289	—	—	15	20	2	—	—	27
Ischemic stroke	D000083242	—	—	1	1	17	—	6	24
Non-small-cell lung carcinoma	D002289	—	—	10	13	2	—	—	23
Heart failure	D006333	EFO_0003144	I50	4	11	3	—	7	22
B-cell chronic lymphocytic leukemia	D015451	—	C91.1	12	13	1	—	—	21

Show 89 more

Indications Phases 2

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Recurrence	D012008	—	—	12	13	—	—	3	26
Bcr-abl positive chronic myelogenous leukemia	D015464	EFO_0000340	—	6	15	—	—	—	20
Hematologic neoplasms	D019337	—	—	10	8	—	—	1	17
Multiple myeloma	D009101	—	C90.0	6	10	—	—	—	14
Hodgkin disease	D006689	—	C81	8	10	—	—	—	14
Colorectal neoplasms	D015179	—	—	8	10	—	—	1	14
Biphenotypic leukemia acute	D015456	—	C95.0	8	10	—	—	—	13
Triple negative breast neoplasms	D064726	—	—	5	7	—	—	1	12
Pancreatic neoplasms	D010190	EFO_0003860	C25	5	6	—	—	—	10
Renal cell carcinoma	D002292	EFO_0000376	—	5	8	—	—	—	10

Show 181 more

Indications Phases 1

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Chronic cough	D000096822	—	R05.3	1	—	—	—	4	5
Magnetic resonance imaging	D008279	—	—	1	—	—	—	4	5
Hyperemia	D006940	EFO_0003822	H34.82	1	—	—	—	3	4
Pharmacokinetics	D010599	—	—	3	—	—	—	—	3
Obsessive-compulsive disorder	D009771	EFO_0004242	F42	1	—	—	—	2	3
Post-traumatic stress disorders	D013313	EFO_0001358	F43.1	1	—	—	—	2	3
Coronary angiography	D017023	—	—	1	—	—	—	1	2
Vasodilation	D014664	—	—	1	—	—	—	1	2
Anxiety disorders	D001008	EFO_0006788	F41.1	1	—	—	—	1	2
Parasomnias	D020447	—	G47.5	1	—	—	—	1	2

Show 58 more

Indications Without Phase

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Malnutrition	D044342	EFO_0008572	E40-E46	—	—	—	—	6	6
Cough	D003371	—	R05	—	—	—	—	4	4
Coronary occlusion	D054059	—	I21	—	—	—	—	3	3
Feeding and eating disorders	D001068	—	F50	—	—	—	—	3	3
Syncope	D013575	—	G90.01	—	—	—	—	3	3
Severe acute malnutrition	D000067011	—	—	—	—	—	—	3	3
Hypertrophy	D006984	EFO_0002460	—	—	—	—	—	3	3
Septic shock	D012772	—	A48.3	—	—	—	—	2	2
Pregnancy	D011247	EFO_0002950	Z33.1	—	—	—	—	2	2
Panic disorder	D016584	EFO_0004262	F41.0	—	—	—	—	2	2

Show 168 more

Epidemiology

Epidemiological information for investigational and approved indications

View more details

Drug

General

Drug common name	Adenosine phosphate
INN	adenosine phosphate
Description	Adenosine 5'-monophosphate is a purine ribonucleoside 5'-monophosphate having adenine as the nucleobase. It has a role as an EC 3.1.3.11 (fructose-bisphosphatase) inhibitor, an EC 3.1.3.1 (alkaline phosphatase) inhibitor, an adenosine A1 receptor agonist, a nutraceutical, a micronutrient, a fundamental metabolite and a cofactor. It is an adenosine 5'-phosphate and a purine ribonucleoside 5'-monophosphate. It is a conjugate base of an adenosine 5'-monophosphate(1+). It is a conjugate acid of an adenosine 5'-monophosphate(2-).
Classification	Small molecule
Drug class	—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)	Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@H]1O